BIO strongly supports a manufacturer’s ability to use a 340B rebate as an appropriate option to make 340B pricing available to covered entities.
"Manufacturers should have the choice to effectuate 340B pricing in the manner they deem most efficient and appropriate under the statute," said BIO's EVP for Health and Policy Programs, Phyllis Arthur. "A 340B rebate is, and should be, among the legally permissible options. We strongly support efforts that could bring the type of transparency needed to protect the integrity of the program.”
A copy of BIO's prior letter to HRSA is available here: https://www.bio.org/letters-testimony-comments/bio-letter-hrsa-340b-rebate-model